Orexin A
hypocretin-1, HCRT-1, orexin-A (human, rat, mouse), prepro-orexin residues 34-66
Orexin A is a 33-amino-acid hypothalamic neuropeptide, also called hypocretin-1, that maintains wakefulness, stabilises the boundary between sleep states, and influences feeding, arousal and reward. Loss of orexin-producing neurons causes narcolepsy type 1. It is a genuine and important human neuropeptide with no cosmetic or dermatological application of any kind; it appears in peptide catalogues purely as a grey-market item.
Mechanism
Orexin A and orexin B are both cleaved from a single 130-residue precursor, prepro-orexin, encoded by HCRT and expressed by a small population of neurons (on the order of 50,000 to 80,000 in humans) confined to the lateral and posterior hypothalamus. Despite that tiny cell number, these neurons project throughout the brain, most importantly to the monoaminergic and cholinergic nuclei that drive arousal: the locus coeruleus, the tuberomammillary nucleus, the dorsal raphe and the laterodorsal and pedunculopontine tegmental nuclei.
Orexin A is heavily modified: its N-terminal glutamine is cyclised to pyroglutamate, its C-terminus is amidated, and two intrachain disulfide bonds lock the N-terminal region into a defined fold. All of these features stabilise the peptide against degradation. It acts at two class A G protein-coupled receptors. OX1R (HCRTR1) is orexin-A-preferring, binding orexin A with roughly an order of magnitude higher affinity than orexin B. OX2R (HCRTR2) binds both peptides with comparable affinity. Both receptors couple predominantly to Gq, activating phospholipase C, raising intracellular calcium and depolarising the target neuron. Orexin signalling is excitatory almost everywhere it acts. Crystallographic work on hOX1R has additionally identified a conserved amphipathic helix in the receptor's extracellular N-terminal region that interacts with orexin-A and is essential for high-potency neuropeptide activation at both receptors.
The division of labour matters. OX2R signalling, particularly in the histaminergic tuberomammillary nucleus, is the principal driver of wakefulness maintenance; OX1R contributes more to REM sleep regulation, and to reward and stress circuitry via the locus coeruleus and ventral tegmental area. In narcolepsy type 1 the orexin neurons are lost, most likely by an autoimmune process, cerebrospinal fluid orexin-A becomes abnormally decreased or undetectable, and the consequences are what the circuit predicts: inability to sustain wakefulness, fragmented sleep, and intrusion of REM phenomena into waking life as cataplexy, sleep paralysis and hypnagogic hallucinations.
What the research shows
Two independent groups identified this system within weeks of each other in 1998. Sakurai and colleagues, working from orphan GPCR deorphanisation, named the peptides orexins for their effect on feeding and characterised both receptors. De Lecea and colleagues, working from hypothalamus-specific transcripts, named the same peptides hypocretins and demonstrated their neuroexcitatory action on cultured hypothalamic neurons. Both names remain in use. The link to narcolepsy followed rapidly.
Human work with the peptide itself is thin, and comes almost entirely from one German group. Baier and colleagues (2008) first showed that narcolepsy with cataplexy patients (n=10) had significantly poorer olfactory threshold, discrimination and identification scores than matched controls, then in a double-blind, randomised, placebo-controlled crossover applied intranasal orexin A to seven of those patients and found the odour detection threshold score increased in all of them relative to placebo. That is an interesting proof that intranasally delivered peptide reaches functionally relevant tissue, but the endpoint has no therapeutic consequence. The same group (2011) ran a double-blind, placebo-controlled, random-order crossover study of intranasal hypocretin-1 (435 nmol) in eight narcolepsy patients before nocturnal polysomnography. Results were mixed: REM sleep quantity was reduced, particularly during the second half of the recording, and direct wake-to-REM transitions fell significantly (a real REM-stabilising effect), but there was no statistically significant effect on nocturnal wakefulness, which was the primary hypothesis. Eight patients is a pilot, and the authors framed it as one.
The decisive clinical development went in a different direction entirely. Orexin receptor antagonists (suvorexant, lemborexant, daridorexant) are approved insomnia treatments, which is the orexin system exploited in reverse. On the agonist side, the successful agents are small molecules, not peptides: Evans and colleagues (2022) reported that the OX2R-selective agonist danavorexton, given by intravenous infusion in single- and multiple-rising-dose studies in healthy adults and in narcolepsy type 1 and type 2 patients, was well tolerated and produced marked improvements in sleep latency, with dose-dependent increases in Maintenance of Wakefulness Test sleep latency up to the 40-minute ceiling in narcolepsy type 1. The lesson is straightforward: the orexin system is a validated drug target, and orexin A itself is not the drug. A large, disulfide-bonded, rapidly cleared peptide with poor blood-brain barrier transit is a poor therapeutic molecule, which is precisely why the field engineered around it.
There is no dermatological, cosmetic or anti-ageing literature on orexin A. Its inclusion in a cosmetic peptide category reflects grey-market retail classification, not biology.
Evidence assessment
Limited evidence
The underlying neurobiology is exceptionally well established, but human data on administering orexin A itself is confined to two very small intranasal pilot studies from one group with partially null results; every clinically successful orexin drug is a small molecule, not the peptide.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Preclinical only
Identified orexin A and orexin B from a common prepro-orexin precursor and characterised OX1R and OX2R, establishing OX1R preference for orexin A and comparable OX2R affinity for both peptides.
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity Preclinical only
Identified the same peptides independently, naming them hypocretins, and demonstrated their neuroexcitatory activity on hypothalamic neurons.
Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1) Limited evidence
Patients scored significantly lower than controls on olfactory threshold, discrimination, identification and TDI score; the odour detection threshold score increased in all patients after intranasal orexin A compared with placebo (P<0.05).
Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy Limited evidence
No statistically significant effect on nocturnal wakefulness. Reduced REM sleep quantity, particularly in the second half of the recording, and significantly reduced direct wake-to-REM transitions.
Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients Mixed evidence
In mice, danavorexton reduced sleep/wake fragmentation and cataplexy-like episodes during the active phase. In humans it was well tolerated and produced marked improvements in sleep latency in both narcolepsy types, with dose-dependent increases in Maintenance of Wakefulness Test sleep latency up to the 40-minute ceiling in narcolepsy type 1.
Safety
No adequate human safety database exists for administered orexin A. The two intranasal pilot studies involved a combined handful of patients over single sessions and are not a safety dataset. What can be inferred from receptor pharmacology, rather than observed, is that systemic orexin receptor agonism would be expected to have sympathoexcitatory and autonomic consequences, and that orexin signalling is involved in stress responses, panic-like states and drug reward circuitry, so agonism is not a neutral intervention. Specific tolerability figures sometimes attributed to the phase 1 danavorexton programme (for example particular blood pressure or urinary effects) could not be verified from the published abstract during this review and are not asserted here.
The absence of adverse reports for peptide sold online reflects the absence of any monitoring, not an absence of risk. Material supplied under 'for research use only' labelling has no verified identity, purity or sterility; for a peptide with two intrachain disulfide bonds and an N-terminal pyroglutamate, correct folding and modification are not incidental details but the difference between an active peptide and inert or misfolded material. Nothing about orexin A supports self-administration.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use would fall under the Human Medicines Regulations 2012 as an unlicensed medicinal product. Orexin receptor antagonists including daridorexant and lemborexant hold UK authorisations for insomnia; no orexin peptide product does. |
| United States | Not FDA-approved for any indication in any form. It is an endogenous human neuropeptide sold as a research reagent. Approved drugs targeting this system are all small molecules and are orexin receptor antagonists for insomnia (suvorexant, lemborexant, daridorexant); OX2R agonists such as danavorexton remain investigational. Supply of orexin A for human use would constitute distribution of an unapproved new drug. |
| WADA (sport) | Prohibited under S0 (Non-Approved Substances), which covers at all times any pharmacological substance not addressed elsewhere on the List and with no current approval by any governmental regulatory health authority for human therapeutic use. A potent wakefulness-promoting agent would in any case attract scrutiny. |
Questions
No, not remotely. Orexin A is a hypothalamic neuropeptide governing wakefulness, arousal, feeding and reward. There is no dermatological or cosmetic literature on it at all. Its appearance alongside skincare peptides reflects how grey-market retailers group their catalogues, not any shared biology.
It has not been shown to. Two small pilot studies from one German group found intranasal orexin A restored olfactory thresholds and stabilised REM sleep, but the 2011 crossover study in eight patients found no significant effect on nocturnal wakefulness, the endpoint that would actually matter. No larger trial followed.
Nothing. Two groups discovered the same peptides independently in 1998 and named them differently: Sakurai's group called them orexins after their effect on feeding, de Lecea's group called them hypocretins after their hypothalamic origin. Orexin A is hypocretin-1; orexin B is hypocretin-2. Both names remain in the literature.
Because they are antagonists. Suvorexant, lemborexant and daridorexant block orexin receptors to permit sleep in insomnia. The agonist side of the target (for narcolepsy) has been pursued with small molecules such as danavorexton rather than with the peptide, because a large disulfide-bonded peptide with poor blood-brain barrier transit makes a poor drug.